ProSomnus Comments On Insurance Coverage Policy Update For Obstructive And Central Sleep Apnea
Portfolio Pulse from Benzinga Newsdesk
ProSomnus, Inc. (NASDAQ:OSA) has welcomed UnitedHealthcare's updated medical policy for Obstructive and Central Sleep Apnea, which now includes oral appliance therapy (OAT) as a prerequisite for Implantable Hypoglossal Nerve Stimulation in adult patients. The policy change, effective March 1, 2024, recognizes the effectiveness of OAT devices like ProSomnus's Precision OAT in treating sleep apnea. Recent studies and patient data support the safety, effectiveness, and patient satisfaction with modern OAT devices, with high success rates reported in clinical trials and follow-ups.
January 08, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProSomnus's Precision OAT devices are now recognized by UnitedHealthcare as a prerequisite therapy for certain sleep apnea treatments, potentially increasing demand for the company's products.
The updated UnitedHealthcare policy directly benefits ProSomnus by potentially increasing the use of its Precision OAT devices as a prerequisite treatment for sleep apnea. This could lead to increased demand and sales for the company's products, positively impacting its revenue in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100